viewOpen Orphan PLC

Open Orphan PLC - Early adopters signed for Genomic Health DataBANK

RNS Number : 4434U
Open Orphan PLC
25 November 2019

25th November 2019

Open Orphan plc

("Open Orphan" or the "Company")

Early adopters signed for Genomic Health DataBANK


Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform. The platform is expected to be completed and rolled out in Q1 2020.

The five companies signed up to the Genomic Health DataBANK platform will ensure the database is 'fit-for-purpose' from a pharmaceutical and data analysis perspective ahead of the first patient data upload. This builds upon our previously announced collaboration with Empiric Logic who will work with the Company to complete the platform.

In conjunction, Open Orphan is working to finalise early adopter agreements with several Patient Advocacy Groups, who will make their patients aware of Open Orphan's Genomic Database.  The Company hopes to make an announcement on this front shortly.

These strategic agreements will allow Open Orphan to deliver on its objective to build Europe's first rare disease, advocacy-led genomic database which will empower patients to directly drive research into their own respective disease.

Maurice Treacy, Chief Commercial Officer of Open Orphan commented:

"We are very excited to be working with these leading pharmaceutical and biotechnology companies on our market leading DataBANK. The Genomic Health DataBANK, which makes extensive use of AI tools, is an innovative research tool for pharmaceutical companies, and we are excited by its potential when launched in early 2020. We believe the DataBANK can ignite research for new diagnostic tools and therapeutic products for rare disease patients."



Open Orphan plc Tel: +353 1 644 0007
Cathal Friel, Chief Executive Officer

Arden Partners (Nominated Adviser and Joint Broker) Tel: +44 (0)20 7614 5900
John Llewellyn-Lloyd / Ruari McGirr / Benjamin Cryer

Davy (Euronext Growth Adviser and Joint Broker) Tel: +353 (0)1 679 6363
Anthony Farrell (Corporate Finance)

Camarco (Financial PR) Tel: +44 (0)20 3757 4980
Tom Huddart / Dan Sherwen


Notes to Editors on Open Orphan:

Open Orphan plc is a European-focused, rare and orphan drug consulting services platform. The Company intends to roll up a number of orphan drug services businesses. Open Orphan has two data driven digital platforms, a Genomic Health Data Platform, which is establishing a rare disease database and a Virtual Rep platform, enabling pharmaceutical companies to engage key opinion leaders and physicians. The Company is targeting rapid growth in one of the fastest growing sectors in the global pharmaceutical industry targeting under-supplied treatment for life threatening or very serious diseases and rare disorders.


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

Quick facts: Open Orphan PLC

Price: 17.125

Market: AIM
Market Cap: £113.99 m

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Open Orphan PLC: Proactive One2One Virtual Conference

Open Orphan PLC's (LON:ORPH) Cathal Friel presents at the Proactive One2One Virtual Conference. The company's a rapidly growing specialist CRO pharmaceutical services company which is a world leader in the testing of vaccines and antivirals through the use of human challenge clinical trials. It...

4 weeks, 1 day ago